NewAmsterdam Pharma Company N.V./$NAMS
1D1W1MYTD1Y5YMAX
Capital at risk
About NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
- Ticker
- $NAMS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 100
- Headquarters
- Naarden, Netherlands
- Website
- www.newamsterdampharma.com
NAMS Metrics
BasicAdvanced
$2.5B
-
-$2.14
0.11
-
Price and volume
Market cap
$2.5B
Beta
0.11
52-week high
$42.21
52-week low
$21.08
Average daily volume
1.3M
Financial strength
Current ratio
9.033
Quick ratio
8.759
Long term debt to equity
0
Total debt to equity
0
Profitability
EBITDA (TTM)
-244.163
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-3,644.21%
Operating margin (TTM)
-3,432.20%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-20.11%
Return on equity (TTM)
-36.81%
Valuation
Price to revenue (TTM)
359.625
Price to book
3.94
Price to tangible book (TTM)
3.94
Price to free cash flow (TTM)
-17.818
Free cash flow yield (TTM)
-5.61%
Free cash flow per share (TTM)
-1.188
Growth
Revenue change (TTM)
-88.87%
Earnings per share change (TTM)
38.74%
3-year revenue growth (CAGR)
-13.40%
3-year earnings per share growth (CAGR)
-18.02%
Bulls say / Bears say
NewAmsterdam received a positive CHMP opinion recommending European marketing authorization for both obicetrapib monotherapy and its fixed-dose combination with ezetimibe, creating a near-term path to commercialization in a large lipid-treatment market. (NewAmsterdam Pharma)
The company had $678.3 million in cash, cash equivalents and marketable securities at June 30, 2026, providing substantial funding for remaining trials, regulatory work and launch preparation without an immediate financing requirement. (NewAmsterdam Pharma)
Multiple company-specific catalysts are approaching: NewAmsterdam expects a PREVAIL interim analysis in the fourth quarter of 2026, RUBENS Phase 3 topline data by year-end 2026, and potential European launches by Menarini following regulatory decisions. (NewAmsterdam Pharma)
Obicetrapib remains exposed to regulatory and clinical execution risk: the July 2026 CHMP opinion covers Europe, while the company still expects a PREVAIL cardiovascular-outcomes interim result in the first quarter of 2027 and has not yet established U.S. approval. (NewAmsterdam Pharma)
The company remains deeply loss-making as it prepares for commercialization; second-quarter 2026 net loss was $64.1 million and first-half net loss was $112.6 million, with continued clinical and commercial spending expected. (SEC)
Shareholder dilution and earnings volatility are material risks: as of June 30, 2026, NewAmsterdam had 19.9 million outstanding options and $54.5 million of derivative warrant liabilities, while six-month share-based compensation was $18.4 million. (SEC)
Data summarised monthly by Lightyear AI. Last updated on 9 Sept 2026.
Upcoming events
No upcoming events
NAMS News
AllArticlesVideos
Funds containing NAMS
AllUSDGBPEUR
Fund name | Fund size | $NAMS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.17% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.17% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
iShares MSCI World Small Cap$WSML | $9B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.